MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 10:07:56 2024-07-01 EDT | ||
| 6.675 EUR | -1.33% |
|
| 1 month | +19.52% | ||
| 3 months | +30.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 6.675 | -1.33% |
| 24-06-28 | 6.765 | +1.35% |
| 24-06-27 | 6.675 | -1.62% |
| 24-06-26 | 6.785 | -3.28% |
| 24-06-25 | 7.015 | +7.35% |
Real-time Euronext Paris
Last update July 01, 2024 at 10:07 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 3ZLMB | |
| ISIN | NLBNPNL2IJ90 |
| Date issued | 2023-09-25 |
| Strike | 503.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.105 € |
|---|---|
| Lowest since issue | 1.815 € |
| Spread | 0.01 € |
| Spread % | 0.15% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- 3ZLMB Certificat
